GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Statera BioPharma Inc (OTCPK:STAB) » Definitions » Tangible Book per Share

Statera BioPharma (Statera BioPharma) Tangible Book per Share : $-0.41 (As of Sep. 2022)


View and export this data going back to 2021. Start your Free Trial

What is Statera BioPharma Tangible Book per Share?

Tangible book value per share is calculated as the total tangible equity divided by Shares Outstanding (EOP). Total tangible equity is calculated as the Total Stockholders Equity minus Preferred Stock minus Intangible Assets. Statera BioPharma's tangible book value per share for the quarter that ended in Sep. 2022 was $-0.41.

Since intangibles such as goodwill cannot be sold when the company liquidates, tangible book value per share is considered more accurate in reflecting how much shareholders will receive when the company liquidates.


Statera BioPharma Tangible Book per Share Historical Data

The historical data trend for Statera BioPharma's Tangible Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Statera BioPharma Tangible Book per Share Chart

Statera BioPharma Annual Data
Trend Dec19 Dec20 Dec21
Tangible Book per Share
-0.16 -0.14 -0.35

Statera BioPharma Quarterly Data
Dec19 Mar20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Tangible Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only -0.14 -0.35 -0.26 -0.36 -0.41

Competitive Comparison of Statera BioPharma's Tangible Book per Share

For the Biotechnology subindustry, Statera BioPharma's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Statera BioPharma's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Statera BioPharma's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Statera BioPharma's Price-to-Tangible-Book falls into.



Statera BioPharma Tangible Book per Share Calculation

Statera BioPharma's Tangible Book Value Per Share for the fiscal year that ended in Dec. 2021 is calculated as

Tangible Book Value per Share=(Total Stockholders Equity-Preferred Stock-Intangible Assets)/Shares Outstanding (EOP)
=(-1.568-0-10.848)/35.4841
=-0.35

Statera BioPharma's Tangible Book Value Per Share for the quarter that ended in Sep. 2022 is calculated as

Tangible Book Value per Share=(Total Stockholders Equity-Preferred Stock-Intangible Assets)/Shares Outstanding (EOP)
=(-10.241-0-10.507)/50.7447
=-0.41

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theoretically it is what the shareholders will receive if the company is liquidated. Total equity is a balance sheet item and equal to total assets less total liabilities of the company. Since intangibles such as goodwill cannot be sold when the company liquidates, tangible book value per share is considered more accurate in reflecting how much shareholders will receive when the company liquidates.


Statera BioPharma  (OTCPK:STAB) Tangible Book per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.


Statera BioPharma Tangible Book per Share Related Terms

Thank you for viewing the detailed overview of Statera BioPharma's Tangible Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Statera BioPharma (Statera BioPharma) Business Description

Traded in Other Exchanges
N/A
Address
4333 Corbett Drive, Suite 1082, Fort Collins, CO, USA, 80525
Statera BioPharma Inc is a pre-clinical and clinical biopharmaceutical company developing multiple product candidates to address unmet medical needs for use in diseases involving immune system dysfunction.
Executives
Satishchandran Chandrasekhar director 167 CARMELA COURT, JUPITER FL 33478
Taunia Markvicka director, officer: Chief Operating Officer 2537 RESEARCH BOULEVARD, SUITE 201, FORT COLLINS CO 80526
Robert Buckheit officer: Chief Technology Officer C/O CYTOCOM INC., 2537 RESEARCH BLVD, SUITE 201, FORT COLLINS CO 80526
Mcavoy Cozette M. officer: Chief Legal Officer 2537 RESEARCH BOULEVARD, SUITE 201, FORT COLLINS CO 80526
Michael K Handley director, officer: President and CEO 9965 FEDERAL DRIVE, COLORADO SPRINGS CO 80921
Clifford Selsky officer: Chief Medical Officer 2537 RESEARCH BOULERVARD, SUITE 201, FORT COLLINS CO 80526
Peter Aronstam officer: Chief Financial Officer 2537 RESEARCH BLVD, SUITE 201, FORT COLLINS CO 80526
Steve K Barbarick director TRACTOR SUPPLY COMPANY, 5401 VIRGINIA WAY, BRENTWOOD TN 37027
Christopher Zosh officer: Vice President of Finance C/O CLEVELAND BIOLABS, INC., 73 HIGH STREET, BUFFALO NY 14203
Ivan Fedyunin director 73 HIGH STREET, BUFFALO NY 14203
John Edward Szydlo officer: Principal Financial Officer 73 HIGH STREET, BUFFALO NY 14203
Alexander Andryushechkin director 73 HIGH STREET, BUFFALO NY 14203
Daniil Talyanskiy director 73 HIGH STREET, BUFFALO NY 14203
Lea Verny director 73 HIGH STREET, BUFFALO NY 14203
Alexey Nechaev director 73 HIGH STREET, BUFFALO NY 14203

Statera BioPharma (Statera BioPharma) Headlines

From GuruFocus